#COVOVAX

[myrawjcsmicasereports]

Rapid progression of angioimmunoblastic t cell lymphoma after Covid-19 vaccination by Iryna Abramenko, MD in Journal of Clinical Case Reports Medical Images and Health Sciences

Abstract

We present the case of a 57-year-old male patient from Ukraine who developed tonsillitis and generalized lymphadenopathy approximately one week after receiving the first dose of the ChAdOx1 (AstraZeneca) anti-SARS-CoV-2 vaccine. A total body computerized tomography scan revealed pronounced lymphadenopathy above and below the diaphragm, and enlargement of the spleen. Histologic examination of the left inguinal lymph node revealed revealed lack of a clear separation of the cortical and paracortical areas. Expanded proliferation of vessels (postcapillary venules) around which atypical lymphoid cells of small and medium size were located. The most of atypical lymphoid cells expressed CD3, CD4, PD1, blc-6, and Ki-67 antigens, some cells also CD10-, CD30-positive. Diagnosis of angioimmunoblastic T-cell lymphoma (AITL), IVB Ann Arbor stage, was established. The patient received six courses of therapy CHOEP regimen. According to the results of treatment clinical and hematological remission is achieved. Thus, this article describes the second case of the development of AITL after vaccination. The accumulation of such data and their analysis will allow to make appropriate conclusions about the relationship of anti-SARS-CoV-2 vaccination with development of oncohematological diseases.

Introduction

SARS-Cov-2 virus infection is widespread throughout the world. By May 2023, the number of infected cases raised to 765,903,278 persons and a total 13,350,530,518 vaccine doses have been administered [1]. Vaccination is an effective mean of preventing infection and the development of severe forms of the disease. Eleven vaccines were recommended by World Health Organization for vaccination: Pfizer-BioNTech, Oxford-AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, CovoVax (Novavax formulation), Convidecia, Sanofi-GSK; a number of vaccines are under consideration [2]. Oxford-AstraZeneca, CoronaVac, Pfizer-BioNTech, and Moderna were used for vaccination against SARS-CoV-2 in Ukraine [3].

Vaccination leads to the development of protective antiviral immunity [4, 5]. In oncological patients, this may have ambivalent influence on tumor growth. Two cases of spontaneous tumor regression after SARS-Cov-2 vaccination have been described: shrinking of the cervical lymph node and resolution of the diffuse lung lesions in patient with a recurrent primary cutaneous anaplastic large-cell lymphoma one week after having received the first COVID-19 vaccination (BioNTech/Pfizer) [6]; and spontaneous regression of metastatic salivary gland myoepithelial carcinoma in patient one month after vaccination of mRNA-1273 COVID-19 (Moderna) vaccine [7]. Anti-cancer effect of COVID-19 vaccines (a decrease in tumor size, a decrease in the expression of tumor markers (VEGF, Ki-67, MMP-2/9), CD4/CD8 ratio, and metastasis to the vital organs) has been shown in 4T1 mice models [8].

On the other hand, cases of progression of oncohematological diseases after vaccination have also been described. Goldman et al. described rapid progression of angioimmunoblastic T cell lymphoma following BNT162b2 mRNA vaccine booster shot [9]. Cavanna et al. presented a case of anaplastic large-cell lymphoma that developed in a patient approximately 10 days after receiving the third dose of the BNT162b2 vaccine and summarized eight additional cases identified in the available literature [10]. There were four cases of diffuse large-B-cell lymphoma [11-13], one case of extranodal NK/T-cell lymphoma [12], one patient with subcutaneous panniculitis-like T-cell lymphoma [14], one case of marginal zone B-cell lymphoma [15] and one primary cutaneous anaplastic large-cell lymphoma  (developed at the SARS-CoV2 vaccine injection site) [16].

In this article, we report a case of angioimmunoblastic T-cell lymphoma developed shortly after SARS-CoV2 vaccination.

Case report

The patient is a 57-year-old Caucasian man with no previous history of disease. On May 6, 2021, he received the first dose of the ChAdOx1 (AstraZeneca). A few days later, he noted a flu-like syndrome and a sore throat. A diagnosis of tonsillitis was established. Antibacterial therapy was ineffective and within two weeks patient noted rapid increase of cervical, axillary, and inguinal lymph nodes. On May, 28, 2021, trephine biopsy of the left inguinal lymph node was performed.

Pathological examination revealed lack of a clear separation of the cortical and paracortical areas. Expanded proliferation of vessels (postcapillary venules) around which atypical lymphoid cells of small and medium size were located. Mitotic figures, single plasma cells, macrophages, neutrophils and eosinophils were present. The most of atypical lymphoid cells expressed CD3, CD4, PD1, blc-6, and Ki-67 antigens, some cells also CD10-, CD30-positive. Small clusters of CD20-positive cells were found between tumor cells. CD21- and CD23-positive follicular dendritic cells wrapped around postcapillary venules. Conclusion (8.06.2021): morphological changes in the lymph node and the immunophenotype of tumor cells correspond to diagnosis of angioimmunoblastic T cell lymphoma.

CT scan (29.05.2021) revealed pronounced lymphadenopathy above and below the diaphragm (diameters of cervical lymph nodes 10-24 mm, paratracheal lymph nodes 8-18 mm, bifurcation lymph nodes 14-25 mm, right axillary lymph nodes up to 20 mm, left axillary lymph nodes up to 15 mm, inguinal lymph nodes 8-28 mm), enlargement of the spleen (5.8x12.0x11.3 cm).

On June, 11, 2021 patient referred to the hematological department of National Research Center for Radiation Medicine. Complaints of the patient upon admission: fever (up to 380C) in the second half of the day, weakness, severe fatigue, enlargement of tonsils and lymph nodes. At examination: ECOG2 performance status. Weight 72 kg. Height 174 cm. Skin is pale. Peripheral lymph nodes are palpable: submaxillary up to 6 cm, cervical 4-6 cm, axillary up to 4 cm, inguinal up to 4 cm in diameter. The liver is not enlarged. The spleen is not palpable. Breathing is vesicular. Systolic murmur over the cardiac apex. The heart rhythm is correct. Blood pressure is 115/75 mm Hg, heart rate is 80 per min. There are no edema.

Bone marrow aspiration (11.06.2021) showed hypercellular marrow, dysplasia in erythropoiesis and megakariocytopoiesis, absence of blast cells, 5.6% of lymphocytes, no cytological signs of leukemic involvement. Among all nuclear bone marrow cells 1.68% with phenotype CD45dim+CD34+CD7+CD5+CD1a-TdT- were quantified by flow cytometry.

Except high level of blood lactate dehydrogenase (1249 units/L), and C-reactive protein (29.8 mg|L) other results of laboratory test of blood and urine were unremarkable.

Diagnosis of angioimmunoblastic T-cell lymphoma (AITL), IVB Ann Arbor stage, was established, and CHOEP (cyclophosphamide, vincristine, doxorubicin, etoposide and prednisone) regimen was initiated. The patient received six courses of therapy CHOEP regimen. According to the results of treatment clinical and hematological remission is achieved: hemodynamic parameters are stable, peripheral lymph nodes are not palpable, the spleen is not enlarged, and the size of the tonsils has decreased significantly.  At the time of this report the patient continues to be in clinical and hematological remission.

Discussion

The most exciting, intriguing question is: can vaccines induce the development of tumors, in particular, lymphoproliferative diseases?

So far, only the development of fibrosarcomas in cats after vaccination is known. This has been proven for killed adjuvanted virus vaccines (vaccination against rabies and feline leukemia virus). An inflammatory process with the formation of granulomatous nodules, only 5% of which subsequently undergo transformation, preceded tumor development. The interval between vaccine administration and detection of sarcoma varied from 4 months to several years [17]. In human, we found three similar cases in the literature: the development of lymphoma and undifferentiated, pleiomorphic high-grade sarcoma at the site of anti-SARS-CoV-2 vaccine administration [16, 18], and peripheral T-cell lymphoma at the injection site of influenza vaccination [19]. However, the interval between vaccine administration and tumor development was short, which does not fit into the classical scheme for the development of the oncological process (initiation, promotion, progression). Thus, it is unclear whether there is a true association between vaccination and the development of malignancy.

For the case described in this article, progression of preceding lymphoma under the influence of the vaccine seems more likely. Anti-SARS-CoV-2 vaccines cause a powerful immune response and stimulation of T- and B-lymphocytes, as well as the production of numerous cytokines [20]. Cases of post vaccine benign lymphadenopathy are described [21]. Today, AITL is recognized as a neoplasm derived from T-follicular helper cells [22, 23]. Up to 75% of AITL patients had a mutation RHOA G17V that facilitates proliferation and activation of several signaling pathways [24]. Since T-follicular helper cells are one of the main targets of mRNA vaccines [25], the Goldman et al. suggested that their stimulation under the influence of the vaccine can accelerate the development of AITL. In their case the malignant cells of patient had a mutation RHOA G17V that could make them especially sensitive to anti-SARS-CoV-2 vaccines [9]. Unfortunately, molecular genetic studies have not been performed in our patient.

Thus, this article describes the second case of the development of AITL after vaccination. The accumulation of such data and their analysis will allow to make appropriate conclusions about the relationship of anti-SARS-CoV-2 vaccination with development of oncohematological diseases. It will contribute to our better understanding of the possible negative consequences of anti-SARS-CoV-2 vaccination and their prevention as well.

[tophindinews]

COVID-19 Covovax: इस वैक्सीन को CoWIN पर दी गई इजाजत, जानिए क्या होगी एक डोज की कीमत - ABP न्यूज़

http://dlvr.it/SmHLlg

[news24fr]

Le Serum Institute of India s'emploie à commercialiser ses deux vaccins clés contre le Covid - Covovax et Covishield - en Chine, qui connaît une résurgence de la pandémie. "Il est très important pour le monde de revenir à ses problèmes de chaîne d'approvisionnement et d'investissement… (donc) il vaut mieux pour le monde que la Chine se remette de cela", a déclaré le chef du SII, Adar Ponawala, à NDTV dans une interview exclusive aujourd'hui. "Nous essayons de nous engager avec la Chine et de leur dire de mettre de côté les différences politiques, les problèmes et les appréhensions et de prendre certains des vaccins occidentaux comme rappel", a-t-il déclaré. Interrogé sur la réponse de la Chine, il a déclaré : "Je pense qu'ils décident de la direction qu'ils veulent prendre... J'espère juste qu'ils décideront rapidement d'une manière ou d'une autre". La nouvelle épidémie en Chine qui a commencé l'année dernière a été attribuée à un cocktail de virus par des experts indiens de la santé. Dans une interview avec NDTV l'année dernière, NK Arora, le chef du panel Covid du Centre, a déclaré: "En Chine, ils n'ont jamais été exposés au virus auparavant, et le vaccin qu'ils ont reçu est probablement moins efficace. La plupart d'entre eux ont reçu trois à quatre doses". M. Poonawalla a déclaré à NDTV que Covovax a fait ses preuves et fonctionne bien contre Omicron. Sa réponse est deux ou trois fois supérieure à celle même de Covishield – l'un des deux vaccins introduits pour la première fois en Inde et dans de nombreux autres pays. Le nouveau vaccin, a déclaré M. Poonawalla, coûtera environ 200 à 300 Rs et sera bientôt sur l'application CoWin du Centre. SII, a déclaré M. Poonawalla, a également soumis des données sur son vaccin contre le paludisme à l'Organisation mondiale de la santé. Le vaccin, a-t-il dit, s'est révélé efficace dans plus de 77% des cas et ils prévoient de le déployer d'ici la fin de l'année en Afrique. Le plus grand fabricant de vaccins en Inde, SII travaille également sur un vaccin contre la dengue, qui est en phase 2-3 d'essais cliniques. Le vaccin, à administrer en trois doses, pourra être prêt dans deux ans, a-t-il ajouté.

[metamarketing-es]

DCGI gives approval to covovax marketing authorization

https://www.twentyfournews.com/2023/01/17/dcgi-gives-approval-to-covovax-marketing-authorization.html?utm_source=dlvr.it&utm_medium=tumblr

[theechudar]

Covid wrap: Govt panel for Covovax jab as heterologous booster dose; worry in China over post-holiday surge among elderly | India News

Covid wrap: Govt panel for Covovax jab as heterologous booster dose; worry in China over post-holiday surge among elderly | India News

NEW DELHI: India’s trend of low rise in daily Covid numbers continued on Thursday, with the country reporting a single-day rise of 197 new cases.Meanwhile, an expert panel of the central drug regulatory authority has recommended market authorisation for Serum Institute of India’s Covid vaccine Covovax as a heterologous booster dose.In China, people are worried about spreading Covid-19 to aged…

[reportwire]

SII stopped Covishield production in Dec 2021, says CEO Adar Poonawalla

SII stopped Covishield production in Dec 2021, says CEO Adar Poonawalla

Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla, on Thursday said the vaccine manufacturer stopped the production of Covishield vaccine starting December 2021, and of the total stock available at that time, around 100 million doses had already got expired. Speaking to reporters on the sidelines of the annual general meeting of Developing Countries Vaccine Manufacturers…

[bidhuan]

BPOM Keluarkan Izin Darurat Vaksin Covovax untuk Booster COVID-19

BPOM Keluarkan Izin Darurat Vaksin Covovax untuk Booster COVID-19

Majalah Farmasetika – Badan Pengawas Obat dan Makanan (BPOM) telah memberi persetujuan perluasan EUA Vaksin Covovax untuk penambahan posologi dosis booster homolog untuk dewasa usia 18 tahun atau lebih pada 19 Agustus 2022. Apa itu vaksin Covovax Vaksin Covovax merupakan vaksin COVID-19 dengan platform protein subunit glikoprotein spike menggunakan adjuvant Matrix-M1 yang dikembangkan Novavax…

[rudrjobdesk]

7-11 साल के बच्चों को लगेगी Covovax, ड्रग्स कंट्रोलर ने दी वैक्सीन के इमरजेंसी इस्तेमाल की मंजूरी- सूत्र

7-11 साल के बच्चों को लगेगी Covovax, ड्रग्स कंट्रोलर ने दी वैक्सीन के इमरजेंसी इस्तेमाल की मंजूरी- सूत्र

नई दिल्ली: ड्रग्स कंट्रोलर जनरल ऑफ इंडिया (DCGI) ने मंगलवार को सीरम इंस्टीट्यूट के कोविड -19 वैक्सीन कोवोवैक्स (Covovax) को कुछ शर्तों के साथ 7 से 11 वर्ष की आयु के बच्चों में इमरजेंसी इस्तेमाल के लि�� मंजूरी दे दी है. सूत्रों ने इसकी जानकारी दी है. वहीं डीसीजीआई ने जेन्नोवा बायोफार्मक्यूटिक्ल की mRNA वैक्सीन की दो डोज को भी आपातकालीन उपयोग के लिए मंजूरी दी है. इसका इस्तेमाल 18 वर्ष से अधिक आयु के…

[vasundharahospital]

वेक्सिनशन सेवाएं #COVOVAX 1st and 2 nd dose 12 - 17 वर्ष के लिए 5 जुन 2022 प्रात 10 बजे से 1 बजे तक (at Jodhpur) https://www.instagram.com/p/CeaaQyzPTbg/?igshid=NGJjMDIxMWI=

[supernews]

Covovax now available for children in India: SII CEO Adar Poonawalla

Serum Institute of India (SII) CEO Adar Poonawalla on Tuesday said that the COVID-19 vaccine Covovax is now available in India for children.

He also hailed Prime Minister Narendra Modi for his vision of providing another vaccine for children.

Covovax (Novavax), is now available for children in India. This is the only vaccine manufactured in India that is also sold in Europe and has an efficacy of 90 per cent. This is in line with Prime Minister Narendra Modi's vision of providing yet another vaccine to protect our children," he said in a tweet.

Last week, the National Technical Advisory Group on Immunisation (NTAGI) approved the Serum Institute of India's Covovax COVID-19 vaccine for the age group 12-17.

However, the Drugs Controller General of India's (DCGI) subject expert committee has sought more data from the Pune-based Serum Institute of India (SII) on the Covovax vaccine for the age group of 7-12 years.

COVID-19 vaccination for minors in India started from January 3 onwards for those in the 15-18 age group with Bharat Biotech's Covaxin. The drive later expanded on March 16 to include children aged above 12 for Biological E's Corbevax.

Read more

[bharatlivenewsmedia]

SEC seeks more data from Serum Institute over Covovax vaccine for 7-12 age group after NTAGI approval: Report

SEC seeks more data from Serum Institute over Covovax vaccine for 7-12 age group after NTAGI approval: Report

SEC seeks more data from Serum Institute over Covovax vaccine for 7-12 age group after NTAGI approval: Report New Delhi: The Drugs Controller General of India’s (DCGI) subject expert committee on Friday sought more data from Pune based Serum Institute of India (SII) on the Covovax vaccine for the age group of 7-12 years. “SEC has sought more data for Covovax vaccine for 7-12 years age group…

[wing-news]

সিরাম ইনস্টিটিউট 12 বছর এবং তার বেশি সময়ের জন্য কোভিড ভ্যাকসিনেশন ড্রাইভে Covovax এর অন্তর্ভুক্তির চেষ্টা করছে

সিরাম ইনস্টিটিউট 12 বছর এবং তার বেশি সময়ের জন্য কোভিড ভ্যাকসিনেশন ড্রাইভে Covovax এর অন্তর্ভুক্তির চেষ্টা করছে

ভারতের ওষুধ নিয়ন্ত্রক 12 থেকে 17 বছর বয়সী গ্রুপের জন্য Covovax-কে সীমিত জরুরী ব্যবহারের অনুমোদন দিয়েছে। Source by [author_name]

[prabudhajanata]

सीरम इंस्टिट्यूट की Covovax को वयस्कों और 12 वर्ष से अधिक उम्र के बच्चों के उपयोग के लिए मिली मंजूरी नई दिल्ली: देश में कोरोना वायरस के खिला...

[aksarnews]

Pharma Stocks Gain After Centre Approves Use Of COVID Pill Molnupiravir

Pharma Stocks Gain After Centre Approves Use Of COVID Pill Molnupiravir

The government also approved two ne vaccines Corbevax and Covovax yesterday Pharmaceutical shares such as Cipla, Dr Reddy’s Laboratories, Torrent Pharmaceuticals, Sun Pharmaceutical Industries gained around two per cent each on Wednesday, December 29, after the Drug Controller General of India (DCGI) approved the emergency use of anti-viral drug – Molnupiravir in the country. to fight against…

[totamil3]

📰 குழந்தைகளுக்கான அவசரகால பயன்பாட்டிற்கான Covovax தடுப்பூசிக்கு WHO இன் ஒப்புதலை சீரம் இன்ஸ்டிடியூட் CEO ஆதார் பூனவல்லா பாராட்டினார்

📰 குழந்தைகளுக்கான அவசரகால பயன்பாட்டிற்கான Covovax தடுப்பூசிக்கு WHO இன் ஒப்புதலை சீரம் இன்ஸ்டிடியூட் CEO ஆதார் பூனவல்லா பாராட்டினார்

கோவிட்க்கு எதிரான போராட்டத்தில் இது மற்றொரு மைல்கல் என்று சீரம் இன்ஸ்டிடியூட் தலைமை நிர்வாக அதிகாரி ஆதார் பூனவல்லா கூறினார். புது தில்லி: கோவிட்-19க்கு எதிரான போராட்டத்தில் “இன்னொரு மைல்கல்லாக” குழந்தைகளுக்கு Covovax தடுப்பூசியை அவசரகாலமாகப் பயன்படுத்துவதற்கு WHO இன் அனுமதியை இந்திய சீரம் இன்ஸ்டிடியூட் (SII) CEO ஆதார் பூனவல்லா வெள்ளிக்கிழமை பாராட்டினார். குறைந்த வருமானம் உள்ள நாடுகளில்…